Targeted Protein Degradation

Global Targeted Protein Degradation Market to Reach US$1.4 Billion by 2030

The global market for Targeted Protein Degradation estimated at US$528.2 Million in the year 2024, is expected to reach US$1.4 Billion by 2030, growing at a CAGR of 17.9% over the analysis period 2024-2030. PROTAC, one of the segments analyzed in the report, is expected to record a 20.8% CAGR and reach US$598.8 Million by the end of the analysis period. Growth in the Molecular Glues segment is estimated at 15.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$143.9 Million While China is Forecast to Grow at 24.8% CAGR

The Targeted Protein Degradation market in the U.S. is estimated at US$143.9 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$334.4 Million by the year 2030 trailing a CAGR of 24.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.9% and 16.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.9% CAGR.

Global Targeted Protein Degradation Market – Key Trends & Drivers Summarized

Why Is Targeted Protein Degradation Redefining Drug Discovery and Therapeutics?

Targeted protein degradation (TPD) has emerged as one of the most promising frontiers in drug discovery, offering a new paradigm in the way diseases—particularly those involving previously “undruggable” targets—can be treated. Unlike conventional small molecule inhibitors that merely block the active sites of proteins, TPD leverages the cell’s own protein degradation machinery to completely eliminate disease-causing proteins from the system. This mechanism offers the potential for deeper and longer-lasting therapeutic effects while expanding the druggable proteome beyond the limits of traditional pharmacology. Central to this approach are heterobifunctional molecules such as PROTACs (Proteolysis-Targeting Chimeras), molecular glues, and other novel modalities that induce selective degradation by recruiting E3 ubiquitin ligases to tag target proteins for proteasomal destruction. This method bypasses the need for a functional binding pocket and allows degradation of scaffolding proteins, transcription factors, and regulatory complexes—many of which are implicated in cancers, neurodegenerative diseases, and immune disorders. The therapeutic implications are profound, enabling researchers to revisit previously abandoned targets and explore new biological pathways. Pharmaceutical companies, biotech innovators, and academic institutions alike are pouring resources into this domain, seeing it not just as a tool, but as a revolutionary platform technology. As the first clinical-stage TPD therapies begin to show encouraging results, the field is poised to redefine the landscape of precision medicine and disease modification.

How Are Technological Innovations Driving the Evolution of TPD Modalities and Platforms?

The field of targeted protein degradation is being rapidly transformed by a wave of technological innovation, which is expanding the chemical diversity, delivery efficiency, and tissue specificity of TPD-based therapeutics. PROTACs, initially limited by size and bioavailability, are now being engineered with improved pharmacokinetics through linker optimization, macrocyclic scaffolds, and structure-guided design techniques. Meanwhile, molecular glues—small molecules that induce protein–protein interactions to promote ubiquitination—are gaining momentum due to their simpler structures and favorable drug-like properties. Advances in structural biology, including cryo-EM and NMR spectroscopy, are enabling a clearer understanding of ternary complex formation, a critical factor in the efficacy of degraders. New screening platforms, such as DNA-encoded libraries, CRISPR-based functional genomics, and high-content phenotypic assays, are helping identify degradable targets and match them with optimal E3 ligase partners. In parallel, tissue-specific ligases and targeted delivery systems are being developed to enhance safety profiles and expand TPD’s applicability beyond oncology. The use of antibody–drug conjugates (ADCs) and nanoparticle delivery vehicles for PROTACs is also under investigation, particularly for targeting the brain and other difficult-to-penetrate tissues. Artificial intelligence and machine learning tools are increasingly being applied to predict degrader efficacy and optimize compound design at scale. These innovations are rapidly converting TPD from an experimental concept into a multi-faceted platform capable of producing first-in-class and best-in-class therapeutics across a wide spectrum of diseases.

Where Is Targeted Protein Degradation Making the Strongest Clinical and Commercial Impact?

Targeted protein degradation is making its most immediate impact in the field of oncology, where many high-value targets—such as BRD4, BCL-XL, and androgen or estrogen receptors—have been successfully degraded in preclinical and early clinical studies. Several PROTAC-based drugs have entered human trials, including candidates targeting prostate cancer, breast cancer, and hematologic malignancies, often showing efficacy where traditional inhibitors have failed or encountered resistance. In addition to cancer, neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and ALS represent a major area of opportunity for TPD, given the involvement of misfolded, aggregated, or intrinsically disordered proteins that are difficult to inhibit but potentially degradable. Autoimmune and inflammatory diseases are also emerging targets, particularly as degraders are developed for cytokine modulators and intracellular immune regulators. The commercial landscape is expanding rapidly, with major pharmaceutical companies entering multi-billion-dollar partnerships with biotech firms that specialize in degrader discovery and optimization. Companies like Arvinas, Kymera Therapeutics, Nurix, and C4 Therapeutics are leading clinical development efforts and have established validated pipelines spanning various therapeutic areas. Beyond the clinical setting, academic research centers are increasingly adopting TPD tools to study protein function and cellular biology, further driving innovation. Geographically, North America dominates early-stage development and funding, but Europe and Asia-Pacific are ramping up investment, regulatory engagement, and institutional collaborations. As intellectual property portfolios grow and first-generation degrader drugs approach regulatory review, the commercial potential of TPD is becoming increasingly tangible, signaling a major shift in how drug pipelines may be shaped in the coming decade.

What’s Fueling the Rapid Growth of the Global Targeted Protein Degradation Market?

The growth of the global targeted protein degradation market is driven by a confluence of scientific breakthroughs, unmet clinical needs, investment momentum, and broadening therapeutic applications. One of the core drivers is the significant ability of TPD to access the large swath of disease-related proteins that have remained unaddressable by conventional small molecules and biologics. The promise of more complete and durable protein silencing makes it a highly attractive option for treating diseases characterized by protein overexpression or mutation-driven pathogenicity. Rising incidence of cancers and chronic illnesses globally is also pushing demand for more selective, resistance-evading therapies—an area where TPD has strong competitive advantage. The influx of venture capital and strategic pharmaceutical partnerships is accelerating pipeline development and pushing more candidates into clinical evaluation. Technological advancements in ligand discovery, linker chemistry, computational modeling, and high-throughput screening are increasing the speed and success rate of degrader development. Regulatory agencies are also showing interest in these novel mechanisms, offering fast-track designations and orphan drug incentives for certain programs, further supporting commercialization. Meanwhile, the growing availability of cell-permeable, orally bioavailable degraders is overcoming previous barriers to adoption. Academic research and early-access TPD toolkits are expanding awareness and enabling non-commercial R&D initiatives, fostering a richer discovery ecosystem. As combination therapies and tissue-specific degraders gain traction, and new E3 ligases are identified and harnessed, the market is set to expand rapidly—positioning targeted protein degradation as a core modality in the future of precision and systems-level therapeutics.

SCOPE OF STUDY:

The report analyzes the Targeted Protein Degradation market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (PROTAC, Molecular Glues, LYTACs, Others); Application (Drug Discovery, Therapy Development); End-Use (Pharma & Biotech Companies, Academic & Research Institutes, Hospitals & Clinical Laboratories, Others)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• Accutar Biotechnology
• AION Labs
• Amphista Therapeutics
• Arvinas, Inc.
• Astellas Pharma Inc.
• AstraZeneca plc
• Bayer AG
• Bio-Techne Corporation
• Bristol-Myers Squibb Company
• C4 Therapeutics, Inc.
• Captor Therapeutics
• Cullgen Inc.
• Draupnir Bio
• F. Hoffmann-La Roche Ltd
• GSK plc
• Halda Therapeutics
• Kymera Therapeutics, Inc.
• Lycia Therapeutics
• Merck KGaA
• Monte Rosa Therapeutics
• Novartis International AG
• Nurix Therapeutics, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.